# Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain

> **NCT00225797** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 160 (—)

## Conditions studied

- Chronic Pain

## Interventions

- **DRUG:** Oxymorphone Extended Release

## Key facts

- **NCT ID:** NCT00225797
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 160 (—)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225797, "Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00225797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*